| 3644- | Sage, | Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers |
| - | Human, | AD, | NA |
| 3645- | Sage, | RosA, | Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family |
| - | Study, | AD, | NA |
| 4217- | Sage, | RosA, | Aroma, | Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2040- | SAHA, | The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | BC, | MCF-7 |
| 4911- | Sal, | MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells |
| - | in-vitro, | Var, | DU145 |
| 4898- | Sal, | Salinomycin as a potent anticancer stem cell agent: State of the art and future directions |
| - | Review, | Var, | NA |
| 4899- | Sal, | Anticancer activity of salinomycin quaternary phosphonium salts |
| - | in-vitro, | Var, | NA |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 4902- | Sal, | OXA, | Salinomycin and oxaliplatin synergistically enhances cytotoxic effect on human colorectal cancer cells in vitro and in vivo |
| - | vitro+vivo, | CRC, | NA |
| 4903- | Sal, | Salinomycin: A new paradigm in cancer therapy |
| - | Review, | Var, | NA |
| 5005- | Sal, | Salinomycin Derivatives Kill Breast Cancer Stem Cells by Lysosomal Iron Targeting |
| - | Review, | Var, | NA |
| 5004- | Sal, | Targeting Telomerase Enhances Cytotoxicity of Salinomycin in Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5003- | Sal, | Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review |
| - | Review, | Var, | NA |
| - | in-vivo, | CRC, | Caco-2 | - | vitro+vivo, | CRC, | CX-1 |
| 5001- | Sal, | Salinomycin exerts anti‐colorectal cancer activity by targeting the β‐catenin/T‐cell factor complex |
| - | in-vitro, | CRC, | NA |
| 5000- | Sal, | Salinomycin kills cancer stem cells by sequestering iron in lysosomes |
| - | vitro+vivo, | BC, | NA |
| 4999- | Sal, | Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells |
| - | in-vitro, | Pca, | PC3 |
| 4997- | Sal, | Salinomycin Treatment Specifically Inhibits Cell Proliferation of Cancer Stem Cells Revealed by Longitudinal Single Cell Tracking in Combination with Fluorescence Microscopy |
| - | in-vitro, | BC, | NA |
| 4996- | Sal, | The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin |
| 4995- | Sal, | Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 4994- | Sal, | Rad, | Salinomycin overcomes radioresistance in nasopharyngeal carcinoma cells by inhibiting Nrf2 level and promoting ROS generation |
| 4904- | Sal, | CUR, | Co-delivery of Salinomycin and Curcumin for Cancer Stem Cell Treatment by Inhibition of Cell Proliferation, Cell Cycle Arrest, and Epithelial–Mesenchymal Transition |
| 4905- | Sal, | Salinomycin as a drug for targeting human cancer stem cells |
| - | Review, | Var, | NA |
| 4906- | Sal, | A Concise Review of Prodigious Salinomycin and Its Derivatives Effective in Treatment of Breast Cancer: (2012–2022) |
| - | Review, | BC, | NA |
| 4907- | Sal, | A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents |
| - | Review, | Var, | NA |
| 4908- | Sal, | Salinomycin triggers prostate cancer cell apoptosis by inducing oxidative and endoplasmic reticulum stress via suppressing Nrf2 signaling |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 4909- | Sal, | Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model |
| - | vitro+vivo, | CRC, | NA |
| 4910- | Sal, | A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent |
| 4912- | Sal, | Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | H157 |
| 4998- | Sal, | Salinomycin may inhibit the cancer stem-like populations with increased chemoradioresistance that nasopharyngeal cancer tumorspheres contain |
| - | in-vitro, | NPC, | NA |
| 5128- | Sal, | Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells |
| - | in-vitro, | AML, | NA |
| 5127- | Sal, | Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway |
| - | in-vitro, | Ovarian, | NA |
| 5126- | Sal, | Salinomycin induces calpain and cytochrome c-mediated neuronal cell death |
| 5125- | Sal, | Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma |
| - | in-vitro, | GBM, | NA |
| 5124- | Sal, | Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance |
| - | in-vitro, | BC, | NA |
| 5123- | Sal, | Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HEK293 |
| 5122- | Sal, | Identification of selective inhibitors of cancer stem cells by high-throughput screening |
| - | in-vivo, | BC, | SUM159 | - | NA, | NA, | 4T1 |
| 5121- | Sal, | Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells |
| - | in-vitro, | BC, | NA |
| 323- | Sal, | AgNPs, | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
| 3939- | SAMe, | VitB12, | ALC, | Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study |
| - | Trial, | NA, | NA |
| 3938- | SAMe, | S-adenosyl-L-methionine in the treatment of Alzheimer's disease |
| - | Human, | AD, | NA |
| 4115- | SAMe, | Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. |
| - | Review, | AD, | NA |
| 4114- | SAMe, | S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research |
| - | Review, | AD, | NA |
| 1210- | SANG, | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer |
| - | in-vitro, | BC, | NA |
| 1209- | SANG, | Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration |
| - | in-vitro, | Lung, | A549 |
| 1208- | SANG, | Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region |
| - | in-vitro, | OS, | NA |
| 1307- | SANG, | Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway |
| - | in-vitro, | CRC, | HT-29 |
| 1090- | SANG, | Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. |
| - | in-vitro, | BC, | MCF-7 |
| 1134- | SANG, | Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 3853- | SAS, | Sulfur-containing therapeutics in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid